SHP2 dysregulations or mutations, especially in the N-SH2 and PTP domains, were observed in many human cancers, such as several types of leukemia and carcinomas, and were found to be positively correlated with tumor initiation and growth [54,55]. This evidence concerns the gene PTPN11 and cancer.